In the current study, consistent with the reports regarding the roles of these three molecules in immunometabolic pathways and liver diseases, our data based on liver tissues from human patients with ACLF validated that FGF19, ADCY8 and KRT17 are upregulated in ACLF and associated with immunometabolic disorder, suggesting that FGF19, ADCY8 and KRT17 could be sensitive biomarkers for the diagnosis of HBV-ALCF. The gene discussed is FGF19; the disease is liver disorder.